Skip to main content
SpringerLink
Log in

Lewy Body Dementia

  • Chapter
  • First Online:
Neurodegenerative Diseases

Abstract

Dementia with Lewy bodies (DLB) represents the second most common cause of neurodegenerative dementia after Alzheimer’s disease (AD).

The dementia with Lewy bodies (DLB) Consortium has refined its recommendations about the clinical and pathologic diagnosis of DLB, updating the previous report, which has been in widespread use for the last decade. The revised DLB consensus criteria now distinguish clearly between clinical features and diagnostic biomarkers and give guidance about optimal methods to establish and interpret these.

Important new information has been updated about previously reported aspects of DLB, with increased diagnostic weighting given to REM sleep behaviour disorder and 123iodine-metaiodobenzylguanidine (MIBG) myocardial scintigraphy. The diagnostic role of other neuroimaging, electrophysiologic and laboratory investigations is also better specified. Substantial progress has been made since the previous report in the detection and recognition of DLB as a common and important clinical disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ballard CG, Holmes C, McKeith IG, O’Brien JT, Ince PG, Perry RH. Clinical symptoms in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer’s disease. Neurology. 1998;50(4):A183.

    Google Scholar 

  2. Olichney JM, Galasko D, Salmon DP, Hofstetter CR, Hansen LA, Katzman R, et al. Cognitive decline is faster in Lewy body variant than in Alzheimer’s disease. Neurology. 1998;51(2):351–7.

    Article  CAS  PubMed  Google Scholar 

  3. Levy R. Alzheimer’s disease and Lewy body dementia. Br J Psychiatry. 1994;164(2):268.

    Article  CAS  PubMed  Google Scholar 

  4. Walker Z, Costa DC, Walker RW, Shaw K, Gacinovic S, Stevens T, et al. Differentiation of dementia with Lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry. 2002;73(2):134–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. O’Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol. 2004;61(6):919–25.

    Google Scholar 

  6. Yoshita M, Taki J, Yokoyama K, Noguchi-Shinohara M, Matsumoto Y, Nakajima K, et al. Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology. 2006;66(12):1850–4.

    Article  CAS  PubMed  Google Scholar 

  7. Lee DR, Taylor JP, Thomas AJ. Assessment of cognitive fluctuation in dementia: a systematic review of the literature. Int J Geriatr Psychiatry. 2012;27(10):989–98.

    Article  PubMed  Google Scholar 

  8. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863–72.

    Google Scholar 

  9. Mollenhauer B, Forstl H, Deuschl G, Storch A, Oertel W, Trenkwalder C. Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions. Dtsc Arztebl Int. 2010;107(39):684–91.

    Google Scholar 

  10. Mosimann UP, Mather G, Wesnes KA, O’Brien JT, Burn DJ, McKeith IG. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology. 2004;63(11):2091–6.

    Article  CAS  PubMed  Google Scholar 

  11. Samuel W, Caligiuri M, Galasko D, Lacro J, Marini M, McClure FS, et al. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry. 2000;15(9):794–802.

    Article  CAS  PubMed  Google Scholar 

  12. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, et al. Dementia with Lewy bodies. Lancet Neurol. 2004;3(1):19–28.

    Article  PubMed  Google Scholar 

  13. Burn DJ, McKeith IG. Current treatment of dementia with Lewy bodies and dementia associated with Parkinson’s disease. Mov Disord. 2003;18(Suppl 6):S72–9.

    Article  PubMed  Google Scholar 

  14. Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613–8.

    Article  CAS  PubMed  Google Scholar 

  15. Emre M, Tsolaki M, Bonuccelli U, Destee A, Tolosa E, Kutzelnigg A, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969–77.

    Article  CAS  PubMed  Google Scholar 

  16. Matsunaga S, Kishi T, Iwata N. Memantine for Lewy body disorders: systematic review and meta-analysis. Am J Geriatr Psych. 2015;23(4):373–83.

    Article  Google Scholar 

  17. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Weisman D, McKeith I. Dementia with Lewy bodies. Semin Neurol. 2007;27(1):42–7.

    Article  PubMed  Google Scholar 

  19. Nakajima K, Okuda K, Yoshimura M, Matsuo S, Wakabayashi H, Imanishi Y, et al. Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations. J Nucl Cardiol. 2014;21(5):970–8.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Treglia G, Cason E. Diagnostic performance of myocardial innervation imaging using MIBG scintigraphy in differential diagnosis between dementia with Lewy bodies and other dementias: a systematic review and a meta-analysis. J Neuroimaging. 2012;22(2):111–7.

    Article  PubMed  Google Scholar 

  21. Yoshita M, Taki J, Yamada M. A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer’s-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2001;71(5):583–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. McCarter SJ, St Louis EK, Duwell EJ, Timm PC, Sandness DJ, Boeve BF, et al. Diagnostic thresholds for quantitative REM sleep phasic burst duration, phasic and tonic muscle activity, and REM atonia index in REM sleep behavior disorder with and without comorbid obstructive sleep apnea. Sleep. 2014;37(10):1649–62.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Frauscher B, Iranzo A, Gaig C, Gschliesser V, Guaita M, Raffelseder V, et al. Normative EMG values during REM sleep for the diagnosis of REM sleep behavior disorder. Sleep. 2012;35(6):835–47.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Boeve BF, Silber MH, Ferman TJ, Lin SC, Benarroch EE, Schmeichel AM, et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med. 2013;14(8):754–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Ratti PL, Negre-Pages L, Perez-Lloret S, Manni R, Damier P, Tison F, et al. Subjective sleep dysfunction and insomnia symptoms in Parkinson’s disease: insights from a cross-sectional evaluation of the French CoPark cohort. Parkinsonism Relat Disord. 2015;21(11):1323–9.

    Article  PubMed  Google Scholar 

  26. Arnulf I. Excessive daytime sleepiness in parkinsonism. Sleep Med Rev. 2005;9(3):185–200.

    Article  PubMed  Google Scholar 

  27. Abbott RD, Ross GW, White LR, Tanner CM, Masaki KH, Nelson JS, et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology. 2005;65(9):1442–6.

    Article  CAS  PubMed  Google Scholar 

  28. Gao J, Huang X, Park Y, Hollenbeck A, Blair A, Schatzkin A, et al. Daytime napping, nighttime sleeping, and Parkinson disease. Am J Epidemiol. 2011;173(9):1032–8.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Simuni T, Caspell-Garcia C, Coffey C, Chahine LM, Lasch S, Oertel WH, et al. Correlates of excessive daytime sleepiness in de novo Parkinson’s disease: a case control study. Mov Disord. 2015;30(10):1371–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Breen DP, Williams-Gray CH, Mason SL, Foltynie T, Barker RA. Excessive daytime sleepiness and its risk factors in incident Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2013;84(2):233–4.

    Article  PubMed  Google Scholar 

  31. Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol. 2015;14(1):57–64.

    Article  PubMed  Google Scholar 

  32. Iranzo A, Fernandez-Arcos A, Tolosa E, Serradell M, Molinuevo JL, Valldeoriola F, et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One. 2014;9(2):e89741.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology. 2009;72(15):1296–300.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Giaquinto S, Nolfe G. The EEG in the normal elderly: a contribution to the interpretation of aging and dementia. Electroencephalogr Clin Neurophysiol. 1986;63(6):540–6.

    Article  CAS  PubMed  Google Scholar 

  35. Breslau J, Starr A, Sicotte N, Higa J, Buchsbaum MS. Topographic EEG changes with normal aging and SDAT. Electroencephalogr Clin Neurophysiol. 1989;72(4):281–9.

    Article  CAS  PubMed  Google Scholar 

  36. Briel RC, McKeith IG, Barker WA, Hewitt Y, Perry RH, Ince PG, et al. EEG findings in dementia with Lewy bodies and Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 1999;66(3):401–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Babiloni C, Del Percio C, Lizio R, Noce G, Cordone S, Lopez S, et al. Abnormalities of cortical neural synchronization mechanisms in patients with dementia due to Alzheimer’s and Lewy body diseases: an EEG study. Neurobiol Aging. 2017;55:143–58.

    Article  PubMed  Google Scholar 

  38. Barber PA, Varma AR, Lloyd JJ, Haworth B, Snowden JS, Neary D. The electroencephalogram in dementia with Lewy bodies. Acta Neurol Scand. 2000;101(1):53–6.

    Article  CAS  PubMed  Google Scholar 

  39. Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG, O’Brien JT, et al. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer’s disease, and vascular dementia. Neurology. 2000;54(8):1616–25.

    Google Scholar 

  40. Walker MP, Ayre GA, Perry EK, Wesnes K, McKeith IG, Tovee M, et al. Quantification and characterization of fluctuating cognition in dementia with Lewy bodies and Alzheimer’s disease. Dement Geriatr Cogn Disord. 2000;11(6):327–35.

    Article  CAS  PubMed  Google Scholar 

  41. Andersson M, Hansson O, Minthon L, Rosen I, Londos E. Electroencephalogram variability in dementia with Lewy bodies, Alzheimer’s disease and controls. Dement Geriatr Cogn Disord. 2008;26(3):284–90.

    Article  CAS  PubMed  Google Scholar 

  42. Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M. EEG comparisons in early Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease with dementia patients with a 2-year follow-up. Brain. 2008;131(Pt 3):690–705.

    Article  PubMed  Google Scholar 

  43. Onofrj M, Thomas A, Iacono D, Luciano AL, Di Iorio A. The effects of a cholinesterase inhibitor are prominent in patients with fluctuating cognition: a part 3 study of the main mechanism of cholinesterase inhibitors in dementia. Clin Neuropharmacol. 2003;26(5):239–51.

    Article  CAS  PubMed  Google Scholar 

  44. Jackson CE, Snyder PJ. Electroencephalography and event-related potentials as biomarkers of mild cognitive impairment and mild Alzheimer’s disease. Alzheimers Dement. 2008;4(1 Suppl 1):S137–43.

    Article  PubMed  Google Scholar 

  45. Lee H, Brekelmans GJ, Roks G. The EEG as a diagnostic tool in distinguishing between dementia with Lewy bodies and Alzheimer’s disease. Clin Neurophysiol. 2015;126(9):1735–9.

    Article  PubMed  Google Scholar 

  46. Kai T, Asai Y, Sakuma K, Koeda T, Nakashima K. Quantitative electroencephalogram analysis in dementia with Lewy bodies and Alzheimer’s disease. J Neurol Sci. 2005;237(1–2):89–95.

    Article  PubMed  Google Scholar 

  47. Bonanni L, Perfetti B, Bifolchetti S, Taylor JP, Franciotti R, Parnetti L, et al. Quantitative electroencephalogram utility in predicting conversion of mild cognitive impairment to dementia with Lewy bodies. Neurobiol Aging. 2015;36(1):434–45.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Bonanni L, Franciotti R, Nobili F, Kramberger MG, Taylor JP, Garcia-Ptacek S, et al. EEG markers of dementia with Lewy bodies: a Multicenter Cohort Study. J Alzheimers Dis. 2016;54(4):1649–57.

    Article  PubMed  Google Scholar 

  49. Dauwan M, van Dellen E, van Boxtel L, van Straaten EC, de Waal H, Lemstra AW, et al. EEG-directed connectivity from posterior brain regions is decreased in dementia with Lewy bodies: a comparison with Alzheimer’s disease and controls. Neurobiol Aging. 2016;41:122–9.

    Article  PubMed  Google Scholar 

  50. van Dellen E, de Waal H, van der Flier WM, Lemstra AW, Slooter AJ, Smits LL, et al. Loss of EEG network efficiency is related to cognitive impairment in dementia with Lewy bodies. Mov Disord. 2015;30(13):1785–93.

    Article  PubMed  Google Scholar 

  51. Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Natl Acad Sci U S A. 2000;97(20):11050–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Lebedev AV, Westman E, Beyer MK, Kramberger MG, Aguilar C, Pirtosek Z, et al. Multivariate classification of patients with Alzheimer’s and dementia with Lewy bodies using high-dimensional cortical thickness measurements: an MRI surface-based morphometric study. J Neurol. 2013;260(4):1104–15.

    Article  PubMed  Google Scholar 

  53. Delli Pizzi S, Franciotti R, Tartaro A, Caulo M, Thomas A, Onofrj M, et al. Structural alteration of the dorsal visual network in DLB patients with visual hallucinations: a cortical thickness MRI study. PLoS One. 2014;9(1):e86624.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Colloby SJ, Cromarty RA, Peraza LR, Johnsen K, Johannesson G, Bonanni L, et al. Multimodal EEG-MRI in the differential diagnosis of Alzheimer’s disease and dementia with Lewy bodies. J Psychiatr Res. 2016;78:48–55.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Blanc F, Colloby SJ, Cretin B, de Sousa PL, Demuynck C, O’Brien JT, et al. Grey matter atrophy in prodromal stage of dementia with Lewy bodies and Alzheimer’s disease. Alzheimers Res Ther. 2016;8:31.

    Google Scholar 

  56. Mak E, Su L, Williams GB, Watson R, Firbank M, Blamire A, et al. Differential atrophy of hippocampal subfields: a comparative study of dementia with Lewy bodies and Alzheimer disease. Am J Geriatr Psychiatry. 2016;24(2):136–43.

    Article  PubMed  Google Scholar 

  57. Delli Pizzi S, Franciotti R, Bubbico G, Thomas A, Onofrj M, Bonanni L. Atrophy of hippocampal subfields and adjacent extrahippocampal structures in dementia with Lewy bodies and Alzheimer’s disease. Neurobiol Aging. 2016;40:103–9.

    Article  PubMed  Google Scholar 

  58. Aminoff EM, Kveraga K, Bar M. The role of the parahippocampal cortex in cognition. Trends Cogn Sci. 2013;17(8):379–90.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Canu E, McLaren DG, Fitzgerald ME, Bendlin BB, Zoccatelli G, Alessandrini F, et al. Microstructural diffusion changes are independent of macrostructural volume loss in moderate to severe Alzheimer’s disease. J Alzheimers Dis. 2010;19(3):963–76.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Mak E, Su L, Williams GB, O'Brien JT. Neuroimaging characteristics of dementia with Lewy bodies. Alzheimers Res Ther. 2014;6(2):18.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Delli Pizzi S, Maruotti V, Taylor JP, Franciotti R, Caulo M, Tartaro A, et al. Relevance of subcortical visual pathways disruption to visual symptoms in dementia with Lewy bodies. Cortex. 2014;59:12–21.

    Article  PubMed  Google Scholar 

  62. Delli Pizzi S, Franciotti R, Taylor JP, Thomas A, Tartaro A, Onofrj M, et al. Thalamic involvement in fluctuating cognition in dementia with Lewy bodies: magnetic resonance evidences. Cereb Cortex. 2015;25(10):3682–9.

    Article  PubMed  Google Scholar 

  63. Sherman SM. The thalamus is more than just a relay. Curr Opin Neurobiol. 2007;17(4):417–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Akeju O, Loggia ML, Catana C, Pavone KJ, Vazquez R, Rhee J, et al. Disruption of thalamic functional connectivity is a neural correlate of dexmedetomidine-induced unconsciousness. elife. 2014;3:e04499.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Klein JC, Eggers C, Kalbe E, Weisenbach S, Hohmann C, Vollmar S, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology. 2010;74(11):885–92.

    Article  CAS  PubMed  Google Scholar 

  66. Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. 1999;22(6):273–80.

    Article  CAS  PubMed  Google Scholar 

  67. Wesnes KA, McKeith I, Edgar C, Emre M, Lane R. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology. 2005;65(10):1654–6.

    Article  CAS  PubMed  Google Scholar 

  68. Saalmann YB, Pinsk MA, Wang L, Li X, Kastner S. The pulvinar regulates information transmission between cortical areas based on attention demands. Science. 2012;337(6095):753–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Erskine D, Taylor JP, Firbank MJ, Patterson L, Onofrj M, O’Brien JT, et al. Changes to the lateral geniculate nucleus in Alzheimer’s disease but not dementia with Lewy bodies. Neuropathol Appl Neurobiol. 2016;42(4):366–76.

    Google Scholar 

  70. Imamura T, Ishii K, Sasaki M, Kitagaki H, Yamaji S, Hirono N, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease: a comparative study using positron emission tomography. Neurosci Lett. 1997;235(1–2):49–52.

    Article  CAS  PubMed  Google Scholar 

  71. Lim SM, Katsifis A, Villemagne VL, Best R, Jones G, Saling M, et al. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med. 2009;50(10):1638–45.

    Article  CAS  PubMed  Google Scholar 

  72. Graff-Radford J, Murray ME, Lowe VJ, Boeve BF, Ferman TJ, Przybelski SA, et al. Dementia with Lewy bodies: basis of cingulate island sign. Neurology. 2014;83(9):801–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Peraza LR, Colloby SJ, Deboys L, O’Brien JT, Kaiser M, Taylor JP. Regional functional synchronizations in dementia with Lewy bodies and Alzheimer’s disease. Int Psychogeriatr. 2016;28(7):1143–51.

    Google Scholar 

  74. Galvin JE, Price JL, Yan Z, Morris JC, Sheline YI. Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease. Neurology. 2011;76(21):1797–803.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Kenny ER, Blamire AM, Firbank MJ, O’Brien JT. Functional connectivity in cortical regions in dementia with Lewy bodies and Alzheimer’s disease. Brain. 2012;135(Pt 2):569–81.

    Article  PubMed  Google Scholar 

  76. Franciotti R, Falasca NW, Bonanni L, Anzellotti F, Maruotti V, Comani S, et al. Default network is not hypoactive in dementia with fluctuating cognition: an Alzheimer disease/dementia with Lewy bodies comparison. Neurobiol Aging. 2013;34(4):1148–58.

    Article  PubMed  Google Scholar 

  77. Peraza LR, Taylor JP, Kaiser M. Divergent brain functional network alterations in dementia with Lewy bodies and Alzheimer’s disease. Neurobiol Aging. 2015;36(9):2458–67.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Sauer J, ffytche DH, Ballard C, Brown RG, Howard R. Differences between Alzheimer’s disease and dementia with Lewy bodies: an fMRI study of task-related brain activity. Brain. 2006;129(Pt 7):1780–8.

    Article  PubMed  Google Scholar 

  79. Taylor JP, Firbank MJ, He J, Barnett N, Pearce S, Livingstone A, et al. Visual cortex in dementia with Lewy bodies: magnetic resonance imaging study. Br J Psychiatry. 2012;200(6):491–8.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Wang HF, JT Y, Tang SW, Jiang T, Tan CC, Meng XF, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015;86(2):135–43.

    Article  PubMed  Google Scholar 

  81. Stinton C, McKeith I, Taylor JP, Lafortune L, Mioshi E, Mak E, et al. Pharmacological management of lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry. 2015;172(8):731–42.

    Article  PubMed  Google Scholar 

  82. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356(9247):2031–6.

    Article  CAS  PubMed  Google Scholar 

  83. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ. 1992;305(6855):673–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, Kales HC. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry. 2015;72(5):438–45.

    Google Scholar 

  85. Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–40.

    Article  CAS  PubMed  Google Scholar 

  86. Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord. 2008;23(15):2248–50.

    Article  PubMed  Google Scholar 

  87. Molloy S, McKeith IG, O’Brien JT, Burn DJ. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2005;76(9):1200–3.

    Google Scholar 

  88. Aarsland D, Perry R, Larsen JP, McKeith IG, O’Brien JT, Perry EK, et al. Neuroleptic sensitivity in Parkinson’s disease and parkinsonian dementias. J Clin Psychiatry. 2005;66(5):633–7.

    Google Scholar 

  89. Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs. 2009;23(6):477–92.

    Article  CAS  PubMed  Google Scholar 

  90. Ikebe S, Harada T, Hashimoto T, Kanazawa I, Kuno S, Mizuno Y, et al. Prevention and treatment of malignant syndrome in Parkinson’s disease: a consensus statement of the malignant syndrome research group. Parkinsonism Relat Disord. 2003;9(Suppl 1):S47–9.

    Article  PubMed  Google Scholar 

  91. Onofrj M, Thomas A. Acute akinesia in Parkinson disease. Neurology. 2005;64(7):1162–9.

    Article  PubMed  Google Scholar 

  92. Thomas A, Iacono D, Luciano AL, Armellino K, Onofrj M. Acute akinesia or akinetic crisis in Parkinson’s disease. Neurol Sci. 2003;24(3):219–20.

    Article  CAS  PubMed  Google Scholar 

  93. Blanc F, Colloby SJ, Philippi N, de Petigny X, Jung B, Demuynck C, et al. Cortical thickness in dementia with Lewy bodies and Alzheimer’s disease: a comparison of prodromal and dementia stages. PLoS One. 2015;10(6):e0127396.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Zhong J, Pan P, Dai Z, Shi H. Voxelwise meta-analysis of gray matter abnormalities in dementia with Lewy bodies. Eur J Radiol. 2014;83(10):1870–4.

    Article  PubMed  Google Scholar 

  95. Koubeissi MZ, Bartolomei F, Beltagy A, Picard F. Electrical stimulation of a small brain area reversibly disrupts consciousness. Epilepsy Behav. 2014;37:32–5.

    Article  PubMed  Google Scholar 

  96. Christopher L, Koshimori Y, Lang AE, Criaud M, Strafella AP. Uncovering the role of the insula in non-motor symptoms of Parkinson’s disease. Brain. 2014;137(Pt 8):2143–54.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Miyasaki JM, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):996–1002.

    Article  CAS  PubMed  Google Scholar 

  98. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry. 2001;158(3):360–9.

    Article  CAS  PubMed  Google Scholar 

  99. Kaasinen V, Joutsa J, Noponen T, Paivarinta M. Akinetic crisis in Parkinson’s disease is associated with a severe loss of striatal dopamine transporter function: a report of two cases. Case Rep Neurol. 2014;6(3):275–80.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Martino G, Capasso M, Nasuti M, Bonanni L, Onofrj M, Thomas A. Dopamine transporter single-photon emission computerized tomography supports diagnosis of akinetic crisis of parkinsonism and of neuroleptic malignant syndrome. Medicine (Baltimore). 2015;94(13):e649.

    Article  CAS  Google Scholar 

  101. Tzoulis C, Tran GT, Schwarzlmuller T, Specht K, Haugarvoll K, Balafkan N, et al. Severe nigrostriatal degeneration without clinical parkinsonism in patients with polymerase gamma mutations. Brain. 2013;136(Pt 8):2393–404.

    Article  PubMed  Google Scholar 

  102. Bonanni L, Onofrj M, Valente EM, Manzoli L, De Angelis MV, Capasso M, et al. Recurrent and fatal akinetic crisis in genetic-mitochondrial parkinsonisms. Eur J Neurol. 2014;21(9):1242–6.

    Article  CAS  PubMed  Google Scholar 

  103. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology. 2009;73(10):768–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuroscience, Imaging and Clinical Sciences, University G. d’Annunzio of Chieti-Pescara, Pescara, Italy

    L. Bonanni, R. Franciotti, S. Delli Pizzi, A. Thomas & M. Onofrj

Authors
  1. L. Bonanni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Franciotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Delli Pizzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Onofrj
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Bonanni .

Editor information

Editors and Affiliations

  1. University of Milan, Fondazione Ca’ Granda, IRCCS Ospedale Policlinico, Milan, Italy

    Daniela Galimberti

  2. University of Milan, Fondazione Ca’ Granda, IRCCS Ospedale Policlinico, Milan, Italy

    Elio Scarpini

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bonanni, L., Franciotti, R., Delli Pizzi, S., Thomas, A., Onofrj, M. (2018). Lewy Body Dementia. In: Galimberti, D., Scarpini, E. (eds) Neurodegenerative Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-72938-1_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-72938-1_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-72937-4

  • Online ISBN: 978-3-319-72938-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation